Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  2003-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0026-0495(03)00109-4PMID 12898477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro.

  2002cited by this paper
• The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

  2002cited by this paper
• Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.

  2002cited by this paper
• Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance

  2001cited by this paper
• In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake.

  2001cited by this paper
• Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.

  2001cited by this paper
• Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance.

  2001cited by this paper
• Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.

  2001cited by this paper
• Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

  2001cited by this paper
• Sampling the intramyocellular triglycerides from skeletal muscle.

  2001cited by this paper
• Intramuscular lipid content is increased in obesity and decreased by weight loss.

  2000cited by this paper
• Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.

  1999cited by this paper
• Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents.

  1999cited by this paper
• Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.

  1998cited by this paper
• Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.

  1997cited by this paper
• Skeletal Muscle Triglyceride Levels Are Inversely Related to Insulin Action

  1997cited by this paper
• Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM

  1997cited by this paper
• Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat

  1997cited by this paper
• Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators*

  1997cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

  1996cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• Mechanisms of fatty acid-induced inhibition of glucose uptake.

  1994cited by this paper
• Analysis of techniques to obtain plasma for measurement of levels of free fatty acids.

  1993cited by this paper
• Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats.

  1990cited by this paper
• Effect of dietary protein on in vivo insulin action and liver glycogen repletion.

  1989cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper
• Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity.

  1987cited by this paper
• Ciglitazone, a New Hypoglycemic Agent

  1986cited by this paper
• Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats

  1983cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper
• On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance

  year unknowncited by this paper

• Insulin interacts with PPARγ agonists to promote bovine adipocyte differentiation.

  2024cites this paper
• Huperzine A as a Potential Therapeutic Drug for Diabetic Nephropathy: Insights from Transcriptome, Metabolome, Microbiome, and Network Pharmacology Analysis.

  2024cites this paper
• The Regulatory Roles of PPARs in Skeletal Muscle Fuel Metabolism and Inflammation: Impact of PPAR Agonism on Muscle in Chronic Disease, Contraction and Sepsis

  2021cites this paper
• Review: Enhancing intramuscular fat development via targeting fibro-adipogenic progenitor cells in meat animals.

  2020cites this paper
• Dietary Supplementation with Pioglitazone Hydrochloride and Resveratrol Improves Meat Quality and Antioxidant Capacity of Broiler Chickens

  2020cites this paper
• Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source

  2019cites this paper
• Saturated and monounsaturated fatty acids in membranes are determined by the gene expression of their metabolizing enzymes SCD1 and ELOVL6 regulated by the intake of dietary fat

  2019cites this paper
• An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease

  2018cites this paper
• Animal Models of Obesity Characterized by Non-alcoholic Fatty Liver Disease (NAFLD)

  2017cites this paper
• Diet induced altered fatty acid composition and the activation of their metabolizing enzymes in mice

  2017cites this paper
• 4',6-dimethoxyisoflavone-7-O-β-D-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor γ (PPARγ) agonist that stimulates adipocyte differentiation.

  2016cites this paper
• Modulation of Fructose-Induced Insulin Resistance Syndrome in Rats by Rosiglitazone and α-Lipoic Acid

  2013cites this paper
• Momordica charantia and its novel polypeptide regulate glucose homeostasis in mice via binding to insulin receptor.

  2013cites this paper
• A Role for PFKFB3/IPFK2 in Overnutrition-Associated Adipose Tissue and Intestine Inflammatory Responses and Insulin Resistance

  2013cites this paper
• Effects of Dietary Thiazolidinedione Supplementation on Growth Performance, Intramuscular Fat and Related Genes mRNA Abundance in the Longissimus Dorsi Muscle of Finishing Pigs

  2013cites this paper
• Rosiglitazone increases fatty acid Δ9-desaturation and decreases elongase activity index in human skeletal muscle in vivo.

  2012cites this paper
• Locating the source of hyperglycemia: Liver versus muscle

  2012cites this paper
• Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats

  2012cites this paper
• The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial

  2012cites this paper
• The effect of PPARδ agonists (HS00098) on serum lipid profiles in diet-induced obese rhesus monkeys

  2012cites this paper
• The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats.

  2012cites this paper
• Not only accumulation, but also saturation status of intramuscular lipids is significantly affected by PPARγ activation

  2012cites this paper
• Effect of Synthetic Ligands of PPAR a , b / d , c , RAR , RXR 3 and LXR on the Fatty Acid Composition of Phospholipids in Mice 4

  2011cites this paper
• Effect of Synthetic Ligands of PPAR α, β/δ, γ, RAR, RXR and LXR on the Fatty Acid Composition of Phospholipids in Mice

  2011cites this paper
• The effect of rosiglitazone on insulin sensitivity and mid‐thigh low‐density muscle in patients with Type 2 diabetes

  2010cites this paper
• Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus.

  2010cites this paper
• Disruption of Inducible 6-Phosphofructo-2-kinase Ameliorates Diet-induced Adiposity but Exacerbates Systemic Insulin Resistance and Adipose Tissue Inflammatory Response*

  2009cites this paper
• DIFFERENTIAL EFFECTS OF IN VIVO PPAR α AND γ ACTIVATION ON FATTY ACID TRANSPORT PROTEINS EXPRESSION AND LIPID CONTENT IN RAT LIVER

  2009cites this paper
• Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.

  2009cites this paper
• Differential effects of chronic, in vivo, PPAR's stimulation on the myocardial subcellular redistribution of FAT/CD36 and FABPpm

  2009cites this paper
• Insulin resistance and impaired functional vasodilation in obese Zucker rats.

  2008cites this paper
• The influence of thiazolidinediones on adipogenesis in vitro and in vivo: potential modifiers of intramuscular adipose tissue deposition in meat animals.

  2008cites this paper
• Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese.

  2008cites this paper
• Utilization of fluorescence tracer in hyperinsulinemic-euglycemic clamp test in mice.

  2008cites this paper
• The Effect of PPARα, PPARδ, PPARγ, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice

  2007cites this paper
• Tissue-Specific Effects of Rosiglitazone and Exercise in the Treatment of Lipid-Induced Insulin Resistance

  2007cites this paper
• Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance.

  2007influential citation
• Immune modulating effects of B-glucan, fish oil and conjugated linoleic acid

  2007cites this paper
• Rosiglitazone Attenuates Liver Inflammation in a Rat Model of Nonalcoholic Steatohepatitis

  2007cites this paper
• The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis

  2007cites this paper
• Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus

  2006cites this paper
• Lipid and lipoprotein dysregulation in insulin resistant states.

  2006cites this paper
• Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle

  2006cites this paper
• Therapeutic interventions for lipid-induced insulin resistance in skeletal muscle: mechanisms of action

  2006influential citation
• Peroxisome Proliferator-Activated Receptor-α,γ-Agonist Improves Insulin Sensitivity and Prevents Loss of Left Ventricular Function in Obese Dyslipidemic Mice

  2006cites this paper
• Lipoprotein Metabolism in Insulin-Resistant States

  2006cites this paper
• Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.

  2006cites this paper
• Free fatty acids increase PGC‐1α expression in isolated rat islets

  2005cites this paper
• Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats

  2005cites this paper
• On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice

  2005cites this paper
• Peroxisome Proliferator-Activated Receptor Agonists Modulate Heart Function in Transgenic Mice with Lipotoxic Cardiomyopathy

  2005cites this paper
• Metabolic Syndrome Tesaglitazar , a dual PPAR / agonist , ameliorates glucose and lipid intolerance in obese Zucker rats

  2005cites this paper
• Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone.

  2005cites this paper
• Free fatty acids increase PGC-1alpha expression in isolated rat islets.

  2005cites this paper
• Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M400426-JLR200

  2005cites this paper
• Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.

  2005cites this paper
• Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor.

  2004cites this paper
• Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle.

  2004cites this paper